Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.

about

Starting hormone therapy immediately after histological diagnosis of breast cancer.Neoadjuvant therapy for breast cancer: updates and proceedings from the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer

P2860

Q48332691-99B62EF6-3700-4731-B68E-1CA8E45E9B96 Q59135407-AC163627-E38D-4B24-B5F3-3D12138E7341

P2860

Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.

Item

http://www.wikidata.org/entity/Q38765017

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Implementing neoadjuvant endoc ...... , HER2-negative breast cancer.

@en

type

Item

label

Implementing neoadjuvant endoc ...... , HER2-negative breast cancer.

@en

prefLabel

Implementing neoadjuvant endoc ...... , HER2-negative breast cancer.

@en

P1476

Implementing neoadjuvant endoc ...... , HER2-negative breast cancer.

@en

P2093

Alexios Matikas

http://www.w3.org/2001/XMLSchema#string

Ilias Michalakis

http://www.w3.org/2001/XMLSchema#string

Vassilis Georgoulias

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.

Genomic index of sensitivity to endocrine therapy for breast cancer.

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

P304

319-326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1288105

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Theodoros Foukakis

P577

2017-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28128984

http://www.w3.org/2001/XMLSchema#string

Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.

about

P2860

P2860

Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698